SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 257281.
  • 2
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 3
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390400.
  • 4
    Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 167885.
  • 5
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896908.
  • 6
    Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 81726.
  • 7
    DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180: 36171.
  • 8
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 93741.
  • 9
    Van Vollenhoven RF, Emery P, Bingham CO, Keystone E, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. In press.
  • 10
    Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34: 14753.
  • 11
    Landesman SH, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 1981; 3 Suppl: S18497.
  • 12
    Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor α therapy and methotrexate. Curr Opin Rheumatol 2008; 20: 2959.
  • 13
    Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 2729.
  • 14
    Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 22579.
  • 15
    Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 6274.
  • 16
    Burns EA, Lum LG, L'Hommedieu G, Goodwin JS. Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination. J Gerontol 1993; 48: B2316.
  • 17
    Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). URL: www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm.
  • 18
    Centers for Disease Control and Prevention. Recommended adult immunization schedule — United States, 2009. URL: www.cdc.gov/mmwr/PDF/wk/mm5753-Immunization.pdf.
  • 19
    Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 113659.
  • 20
    Pneumovax package insert. Whitehouse Station (NJ): Merck; 2008.
  • 21
    Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 1999; 30: 597623.
  • 22
    Galazka A. The Immunological Basis for Immunization Series Module 3: Tetanus. Geneva: World Health Organization. URL: http://www.who.int/vaccines-documents/DocsPDF-IBI-e/mod3_e.pdf. 1993 (WHO/EPI/Gen 93.13).
  • 23
    Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293: 300311.
  • 24
    Go ES, Ballas ZK. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996; 98: 20515.
  • 25
    Candin Candida Albicans Skin Test Antigen for Cellular Hypersensitivity package insert. Allermed Laboratories, Inc. April 2000.
  • 26
    Fan PT, Yu DT, Clements PJ, Fowlston S, Eisman J, Bluestone R. Effect of corticosteroids on the human immune response: comparison of one and three daily 1 gm intravenous pulses of methylprednisolone. J Lab Clin Med 1978; 91: 62534.
  • 27
    Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al. Variability in the biological response to anti-CD20 B-cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 172431.
  • 28
    Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77: 216573.
  • 29
    Withers DR, Fiorini C, Fischer RT, Ettinger R, Lipsky PE, Grammer AC. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood 2007; 109: 485664.
  • 30
    Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005; 5: 507.
  • 31
    Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 2001; 98: 1759.
  • 32
    Emery P, Panayi G, Symmons D, Brown G. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 1984; 43: 4304.
  • 33
    Siber GR, Santosham M, Reid GR, Thompson C, Almeido-Hill J, Morell A, et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990; 323: 138792.
  • 34
    Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 67688.
  • 35
    Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 265261.
  • 36
    Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31: 135661.
  • 37
    Ahmed AR, Blose DA. Delayed-type hypersensitivity skin testing: a review. Arch Dermatol 1983; 119: 93445.
  • 38
    Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 10611.
  • 39
    Handwerger B, Kafka S, Dhillon G, Thomson G, Dunn M, Ferbas J, et al. Effects of Anakinra (KINERET) on vaccine response in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2004; 50 Suppl: S564.
  • 40
    Ravikumar R, Anolik J, Looney RJ. Vaccine responses in patients with rheumatoid arthritis. Curr Rheumatol Rep 2007; 9: 40715.